Penetratin-functionalized PEG-PLA nanoparticles for brain drug delivery.

Nanoparticulate drug delivery system possesses distinct advantages for brain drug delivery. However, its amount that reach the brain is still not satisfied. Cell-penetrating peptides (CPPs), short peptides that facilitate cellular uptake of various molecular cargo, would be appropriate candidates for facilitating brain delivery of nanoparticles. However, such effect could be deprived by the rapid systemic clearance of CPPs-functionalized nanoparticles due to their positive surface charge. Penetratin (CPP with relatively low content of basic amino acids) was here functionalized to poly(ethylene glycol)-poly(lactic acid) nanoparticles (NP) to achieve desirable pharmacokinetic and biodistribution profiles for brain drug delivery. The obtained penetratin-NP showed a particle size of 100 nm and zeta potential of -4.42 mV. The surface conjugation of penetratin was confirmed by surface chemical compositions analysis via X-ray photo electron spectroscopy. In MDCK-MDR cell model, penetratin-NP presented enhanced cellular accumulation via both lipid raft-mediated endocytosis and direct translocation processes with the involvement of Golgi apparatus, lysosome and microtubules. In vivo pharmacokinetic and biodistribution studies showed that penetratin-NP exhibited a significantly enhanced brain uptake and reduced accumulation in the non-target tissues compared with low-molecular-weight protamine (CPP with high arginine content)-functionalized nanoparticles. These data strongly implicated that penetratin-NP might represent a promising brain-targeting drug delivery system. The findings also provided an important basis for the optimization of brain drug delivery systems via surface charge modulation.

[1]  H. Sprong,et al.  The blood–brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells , 2005, Journal of neurochemistry.

[2]  J. P. Woods,et al.  Monitoring internalization of Histoplasma capsulatum by mammalian cell lines using a fluorometric microplate assay. , 2000, Medical mycology.

[3]  Xiuli Wang,et al.  Synthesis, in vitro and in vivo characterization of glycosyl derivatives of ibuprofen as novel prodrugs for brain drug delivery , 2009, Journal of drug targeting.

[4]  Xin-guo Jiang,et al.  Quantum dots for tracking cellular transport of lectin-functionalized nanoparticles. , 2008, Biochemical and biophysical research communications.

[5]  D. Castner,et al.  Limits of detection for time of flight secondary ion mass spectrometry (ToF-SIMS) and X-ray photoelectron spectroscopy (XPS): detection of low amounts of adsorbed protein , 2002, Journal of biomaterials science. Polymer edition.

[6]  E. Hansson,et al.  Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.

[7]  M Gumbleton,et al.  Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. , 2001, Journal of pharmaceutical sciences.

[8]  Wei Lu,et al.  Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[9]  R. Vandenbroucke,et al.  Title: the Use of Inhibitors to Study Endocytic Pathways of Gene Carriers: Optimisation and Pitfalls the Use of Inhibitors to Study Endocytic Pathways of Gene Carriers: Optimisation and Pitfalls Dries Vercauteren , 2022 .

[10]  U. Haberkorn,et al.  The pharmacokinetics of cell-penetrating peptides. , 2010, Molecular pharmaceutics.

[11]  W. Pardridge.  Blood-brain barrier biology and methodology. , 1999, Journal of neurovirology.

[12]  H. Lee,et al.  Synthesis of Pegylated Immunonanoparticles , 2002, Pharmaceutical Research.

[13]  H. Kusuhara,et al.  Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1). , 2001, Drug discovery today.

[14]  Wei Lu,et al.  Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. , 2006, Biomaterials.

[15]  R. Bendayan,et al.  Multidrug Resistance-Associated Proteins: Expression and Function in the Central Nervous System , 2006, Pharmacological Reviews.

[16]  Hu Yang,et al.  Nanoparticle-Mediated Brain-Specific Drug Delivery, Imaging, and Diagnosis , 2010, Pharmaceutical Research.

[17]  M. Alonso,et al.  Stealth PLA-PEG Nanoparticles as Protein Carriers for Nasal Administration , 1998, Pharmaceutical Research.

[18]  W. Pardridge.  The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[19]  A. Gräslund,et al.  Conformational states of the cell-penetrating peptide penetratin when interacting with phospholipid vesicles: effects of surface charge and peptide concentration. , 2002, Biochimica et biophysica acta.

[20]  Xinguo Jiang,et al.  Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration. , 2011, Biomaterials.

[21]  Xin-guo Jiang,et al.  The association of autophagy with polyethylenimine-induced cytotoxicity in nephritic and hepatic cell lines. , 2011, Biomaterials.

[22]  J. Scherrmann,et al.  CNS Delivery Via Adsorptive Transcytosis , 2008, The AAPS Journal.

[23]  Leaf Huang,et al.  Pharmacokinetics and biodistribution of nanoparticles. , 2008, Molecular pharmaceutics.

[24]  Shana O Kelley,et al.  Recent advances in the use of cell-penetrating peptides for medical and biological applications. , 2009, Advanced drug delivery reviews.

[25]  Feng Liu,et al.  Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. , 2005, Advanced drug delivery reviews.

[26]  M. Zegers,et al.  Actin filaments and microtubules are involved in different membrane traffic pathways that transport sphingolipids to the apical surface of polarized HepG2 cells. , 1998, Molecular biology of the cell.

[27]  V. Labhasetwar,et al.  TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. , 2008, Biomaterials.

[28]  L. Lim,et al.  Mechanistic study of the uptake of wheat germ agglutinin-conjugated PLGA nanoparticles by A549 cells. , 2004, Journal of pharmaceutical sciences.

[29]  Yan Zhang,et al.  Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[30]  B. Veronesi.  Characterization of the MDCK cell line for screening neurotoxicants. , 1996, Neurotoxicology.

[31]  I. Hidalgo,et al.  Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. , 2005, International journal of pharmaceutics.

[32]  Leslie Z. Benet,et al.  Characterization of P-glycoprotein Mediated Transport of K02, a Novel Vinylsulfone Peptidomimetic Cysteine Protease Inhibitor, Across MDR1-MDCK and Caco-2 Cell Monolayers , 1998, Pharmaceutical Research.

[33]  P. Naidoo,et al.  Exploring the use of novel drug delivery systems for antiretroviral drugs. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[34]  Ulo Langel,et al.  Cell-penetrating peptides: mechanism and kinetics of cargo delivery. , 2005, Advanced drug delivery reviews.

[35]  S. Futaki.  Arginine-rich peptides: potential for intracellular delivery of macromolecules and the mystery of the translocation mechanisms. , 2002, International journal of pharmaceutics.

[36]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[37]  A. Prochiantz,et al.  Trojan peptides: the penetratin system for intracellular delivery. , 1998, Trends in cell biology.

[38]  M. Wirth,et al.  Lectin-mediated drug delivery: binding and uptake of BSA-WGA conjugates using the Caco-2 model. , 2002, International journal of pharmaceutics.

[39]  Brian Storrie,et al.  Capacity of the Golgi apparatus for cargo transport prior to complete assembly. , 2006, Molecular biology of the cell.

[40]  D. Luo,et al.  Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. , 2008, Biomaterials.

[41]  J. Suh,et al.  Gene delivery to differentiated neurotypic cells with RGD and HIV Tat peptide functionalized polymeric nanoparticles. , 2006, Biomaterials.

[42]  P. Couvreur,et al.  Long-Circulating PEGylated Polycyanoacrylate Nanoparticles as New Drug Carrier for Brain Delivery , 2001, Pharmaceutical Research.